Repros in the News

Repros Therapeutics to participate as a Sponsor -- developing a therapy specifically designed to treat secondary hypogonadism THE WOODLANDS, Texas , Sept. 26, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today noted that it will participate as a sponsor in a forthcoming

UK designated as rapporteur and France as co-rapporteur Average time to approval 13 - 16 months THE WOODLANDS, Texas , Sept. 12, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that, as anticipated, it has activated the process for obtaining a marketing

Subjects with moderate to severe endometriosis experienced relief of menstrual pain and a reduction in the use of pain medication with the use of Proellex® Proellex® subjects' menstrual pain by BBSS decreased significantly when compared to those treated with placebo Total pain medication

Six month interim assessment of testosterone (T) levels shows statistically and clinically significant increases in total T (p = 0.0017) and free T (p = 0.0020) superior to placebo Effects of diet and exercise and enclomiphene treatment are additive Diet and exercise alone increased mean total T

THE WOODLANDS, Texas , Aug. 09, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. ® (Nasdaq:RPRX) today announced financial results for the second quarter ended June 30, 2016 . Financial Results Net loss for the three month period ended June 30, 2016 , was ($4.3) million or ( $0.18 ) per share

EU submission on track with anticipated registration decision expected Fall 2017 UK designated as rapporteur and France as co-rapporteur for the centralized review of the enclomiphene marketing application 3 month interim assessment of testosterone levels in obese men participating in Phase 2 diet

Primary endpoint of induction of amenorrhea met for the pooled oral doses compared to placebo, p=0.0004 Proellex ® -treated subjects reported a median 100% (mean 95%) reduction in diary reports of menstrual bleeding product usage (PBAC) Statistically significant reduction in fibroid size from

THE WOODLANDS, Texas , May 16, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. ® (Nasdaq:RPRX) today announced that it has appointed Mr. Patrick Fourteau to its Board of Directors, where he will serve as Chairman of the Board. Mr. Fourteau is a seasoned pharmaceutical industry executive

THE WOODLANDS, Texas , May 10, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. ® (Nasdaq:RPRX) today announced financial results for the first quarter ended March 31, 2016 . Financial Results Net loss for the three month period ended March 31, 2016 was ($4.8) million , or ( $0.20 ) per

Primary endpoint of induction of amenorrhea met for both vaginal doses compared to placebo, p < 0.0011 Proellex ® -treated subjects reported a median 100% reduction in diary reports of menstrual bleeding product usage (PBAC) Statistically significant reduction in fibroid size from baseline

THE WOODLANDS, Texas , March 15, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that it has formally activated the process for obtaining marketing authorization for enclomiphene in the treatment of secondary hypogonadism by the European Medicines Agency (EMA).

THE WOODLANDS, Texas , March 14, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. ® (Nasdaq:RPRX) today announced financial results for the fourth quarter and year ended December 31, 2015 . Financial Results Net loss for the three month period ended December 31, 2015 , was ($6.3) million or (

Phase 2 proof of concept study in obese men to assess drug impact on metabolic and quality of life parameters under a rigorous diet and exercise regimen Analyses at 3, 6 and 12 month time points Topline interim results for 3 and 6 months expected summer 2016 THE WOODLANDS, Texas , Feb.

THE WOODLANDS, Texas , Feb. 08, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that on February 4, 2016 , the Company attended a productive meeting with FDA reviewers and senior leaders to discuss resolution of issues identified during the enclomiphene NDA

THE WOODLANDS, Texas , Jan. 11, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that the United States Court of Appeals for the Federal Circuit summarily affirmed the ruling of the United States District Court for the Southern District of Texas in favor of the

Repros expects to meet with FDA to discuss "Complete Response Letter" for enclomiphene NDA during February 2016 Marketing Authorization Application (MAA) for enclomiphene planned for submission in Europe mid-2016 THE WOODLANDS, Texas , Jan. 04, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics

Topline results after first four months of treatment from all three Proellex® trials expected to be available by end of Q3'16 Screening for low dose study for oral Proellex® for uterine fibroids completed with last patient expected to be randomized by end of January ‘16 Initial

THE WOODLANDS, Texas , Dec. 1, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application for enclomiphene for the treatment of secondary

THE WOODLANDS, Texas , Nov. 12, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has completed randomization for its Phase 2b study of Proellex® in the treatment of women suffering with symptomatic uterine fibroids.

THE WOODLANDS, Texas , Nov. 9, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. ® (Nasdaq:RPRX) today announced financial results for the third quarter ended September 30, 2015 . Financial Results Net loss for the three month period ended September 30, 2015 , was ($6.6) million or ( $0.27 )